BR0309283A - Preparação lìquida compreendendo derivado de camptotecina e composição farmacêutica produzìvel por liofilização da preparação - Google Patents

Preparação lìquida compreendendo derivado de camptotecina e composição farmacêutica produzìvel por liofilização da preparação

Info

Publication number
BR0309283A
BR0309283A BR0309283-6A BR0309283A BR0309283A BR 0309283 A BR0309283 A BR 0309283A BR 0309283 A BR0309283 A BR 0309283A BR 0309283 A BR0309283 A BR 0309283A
Authority
BR
Brazil
Prior art keywords
preparation
lyophilization
pharmaceutical composition
liquid preparation
composition produced
Prior art date
Application number
BR0309283-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Takahiro Itoh
Shinji Narisawa
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of BR0309283A publication Critical patent/BR0309283A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
BR0309283-6A 2002-04-16 2003-04-15 Preparação lìquida compreendendo derivado de camptotecina e composição farmacêutica produzìvel por liofilização da preparação BR0309283A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002112864 2002-04-16
PCT/JP2003/004745 WO2003086471A2 (en) 2002-04-16 2003-04-15 Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin

Publications (1)

Publication Number Publication Date
BR0309283A true BR0309283A (pt) 2005-02-15

Family

ID=29243336

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309283-6A BR0309283A (pt) 2002-04-16 2003-04-15 Preparação lìquida compreendendo derivado de camptotecina e composição farmacêutica produzìvel por liofilização da preparação

Country Status (21)

Country Link
US (1) US20050215485A1 (enExample)
EP (1) EP1501549A2 (enExample)
JP (1) JP3927954B2 (enExample)
KR (1) KR100700963B1 (enExample)
CN (1) CN100544769C (enExample)
AR (1) AR039272A1 (enExample)
AU (1) AU2003223120B2 (enExample)
BR (1) BR0309283A (enExample)
CA (1) CA2480425A1 (enExample)
HR (1) HRP20040894A2 (enExample)
ME (1) MEP31308A (enExample)
MX (1) MXPA04010178A (enExample)
MY (1) MY136696A (enExample)
NO (1) NO20044964L (enExample)
PL (1) PL371677A1 (enExample)
RS (1) RS91204A (enExample)
RU (1) RU2315623C2 (enExample)
TW (1) TW200306314A (enExample)
UA (1) UA77295C2 (enExample)
WO (1) WO2003086471A2 (enExample)
ZA (1) ZA200408008B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556254A1 (en) * 2004-02-13 2005-08-25 Kabushiki Kaisha Yakult Honsha Aqueous solution preparation containing camptothecins
CA2562904C (en) 2004-04-27 2013-07-02 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
US7767200B2 (en) 2005-07-14 2010-08-03 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
JP2007260275A (ja) * 2006-03-29 2007-10-11 Transcutaneous Technologies Inc イオントフォレーシス装置及びイオントフォレーシス投与用組成物
BRPI1011753B8 (pt) 2009-06-22 2021-05-25 Wyeth Llc conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem
MX343111B (es) 2009-06-22 2016-10-25 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus.
CN102764260B (zh) * 2011-04-30 2014-07-30 正大天晴药业集团股份有限公司 一种喜树碱衍生物的药物组合物及其制备方法
JP5983608B2 (ja) * 2011-07-15 2016-09-06 コニカミノルタ株式会社 溶解助剤を利用したリポソーム含有製剤およびその製造方法
JP6012902B1 (ja) 2014-12-26 2016-10-25 日本化薬株式会社 カンプトテシン類高分子誘導体の医薬製剤
EP3345654A4 (en) * 2015-09-03 2019-05-08 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL COMPOSITION COMPRISING A CAMPTOTHECINPOLYMER DERIVATIVE
WO2017053920A1 (en) 2015-09-25 2017-03-30 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
RU2018129760A (ru) 2016-03-01 2020-04-01 Ниппон Каяку Кабусики Кайся Фармацевтический препарат, содержащий полимерное производное на основе камптотецина
CN109481691A (zh) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 吉西他滨-羧甲基多糖共轭物、制备方法及其用途
EP4438062A1 (en) * 2021-11-26 2024-10-02 Astellas Pharma Inc. Indocyanine compound-containing solid pharmaceutical composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
ATE136898T1 (de) * 1991-10-29 1996-05-15 Glaxo Wellcome Inc Wasserlösliche camptothecinderivate
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
AR030207A1 (es) * 2000-04-07 2003-08-13 Daiichi Seiyaku Co Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
US6815435B2 (en) * 2000-07-13 2004-11-09 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing DDS compounds
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor

Also Published As

Publication number Publication date
AU2003223120A2 (en) 2003-10-27
RU2315623C2 (ru) 2008-01-27
CA2480425A1 (en) 2003-10-23
MY136696A (en) 2008-11-28
NO20044964L (no) 2004-11-15
UA77295C2 (en) 2006-11-15
KR100700963B1 (ko) 2007-03-28
TW200306314A (en) 2003-11-16
AU2003223120B2 (en) 2006-10-05
AU2003223120A1 (en) 2003-10-27
WO2003086471A3 (en) 2004-04-15
CN100544769C (zh) 2009-09-30
US20050215485A1 (en) 2005-09-29
MXPA04010178A (es) 2005-06-08
RU2004133349A (ru) 2005-05-27
HRP20040894A2 (en) 2005-10-31
JP2005523329A (ja) 2005-08-04
KR20050000516A (ko) 2005-01-05
CN1646172A (zh) 2005-07-27
RS91204A (sr) 2006-12-15
AR039272A1 (es) 2005-02-16
MEP31308A (en) 2010-10-10
WO2003086471A2 (en) 2003-10-23
EP1501549A2 (en) 2005-02-02
PL371677A1 (en) 2005-06-27
JP3927954B2 (ja) 2007-06-13
ZA200408008B (en) 2005-06-13

Similar Documents

Publication Publication Date Title
BR0309283A (pt) Preparação lìquida compreendendo derivado de camptotecina e composição farmacêutica produzìvel por liofilização da preparação
DE69601841D1 (de) Camptothecinderivate
BR0010520A (pt) Novos compostos farmaceuticamente ativos
GR3037076T3 (en) Camptothecin derivatives
KR920703558A (ko) 메타-치환 페닐알라닌 유도체
BR0111377A (pt) Derivados de tiofeno úteis como agentes anticancerìgenos
BR0114436A (pt) Composto com anel de cinco elementos contendo nitrogênio alifático
BR0317600A (pt) ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
BR0014116A (pt) Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR9916781A (pt) 4-oxo-1,4-dihidro-3-quinolinacarboxamidas comoagentes antivirais
AU4831899A (en) 5-HT1F agonists
BR0210293A (pt) Uma preparação farmacêutica aquosa de cilostazol para utilização parenteral
BR0006299A (pt) Derivados da 4-oxo-2-ureìdo-1,4,5,6-tetra-hidro-pirimidina
BR0115454A (pt) Composto de 1-metilcarbapenem ou um sal ou derivado de éster deste farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou de um sal ou derivado de éster deste farmaceuticamente aceitável
BR9807506A (pt) Derivados de amida e composições medicinais dos mesmos
BR0008479A (pt) Agonistas de 5-ht 1f
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций
BRPI0411057A (pt) análogos de prostaglandina e de piperidinila
EA200600270A1 (ru) Применение производных 2h-[1,3]-оксазино[3,2-a]индола для лечения невропатической боли
BR9713618A (pt) Derivados da eritromicina, seu processo de preparo e sua aplicação como medicamentos
DE60126638D1 (de) Bisphosphonsäurederivate zur stärkung von kortikalknochen
PT835265E (pt) Inibidores da agregacao plaquetaria contendo residuos de aminoacidos de cadeia lateral aminergica c-terminal
MX9603149A (es) Derivados de camptotecina.
TH62584A (th) สารละลายเมลอกซิแคมที่เสถียรชนิดเข้มข้นสูงสำหรับการฉีดแบบไม่ใช้เข็ม

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MITSUBISHI TANABE PHARMA CORPORATION (JP)

Free format text: ALTERADO DE: TANABE SEIYAKU CO., LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. A61K 47/48, A61K 47/12, A61K 47/02, A61P 35/00

Ipc: A61K 47/48 (2011.01), A61K 47/12 (2011.01), A61K 4

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.

B15K Others concerning applications: alteration of classification

Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: A61K 47/48; A61K 47/12; A61K 47/02; A61P 35/00.

Ipc: A61K 9/00 (2006.01), A61K 47/02 (2006.01), A61K 47

Ipc: A61K 9/00 (2006.01), A61K 47/02 (2006.01), A61K 47